Department of Hematology, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310009, P. R. China.
Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Life Sciences Institute, Zhejiang University, Hangzhou, Zhejiang, 310058, P. R. China.
Cancer Commun (Lond). 2022 Jun;42(6):493-516. doi: 10.1002/cac2.12313. Epub 2022 Jun 1.
Over the last two decades, several epi-drugs, immune checkpoint inhibitors (ICIs) and adoptive cell therapies have received clinical approval for use in certain types of cancer. However, monotherapy with epi-drugs or ICIs has shown limited efficacy in most cancer patients. Epigenetic agents have been shown to regulate the crosstalk between the tumor and host immunity to alleviate immune evasion, suggesting that epi-drugs can potentially synergize with immunotherapy. In this review, we discuss recent insights into the rationales of incorporating epigenetic therapy into immunotherapy, called epi-immunotherapy, and focus on an update of current clinical trials in both hematological and solid malignancies. Furthermore, we outline the future challenges and strategies in the field of cancer epi-immunotherapy.
在过去的二十年中，已经有几种 epi 药物、免疫检查点抑制剂（ICIs）和过继细胞疗法获得了临床批准，用于治疗某些类型的癌症。然而，epi 药物或 ICI 的单药治疗在大多数癌症患者中的疗效有限。已经表明，表观遗传药物可以调节肿瘤与宿主免疫之间的串扰，以减轻免疫逃逸，这表明 epi 药物有可能与免疫疗法协同作用。在这篇综述中，我们讨论了将表观遗传学治疗纳入免疫疗法（称为 epi-免疫疗法）的合理性的最新见解，并重点介绍了血液系统恶性肿瘤和实体恶性肿瘤中当前临床试验的最新进展。此外，我们还概述了癌症 epi-免疫疗法领域的未来挑战和策略。
